Both toric IOLs and peripheral corneal relaxing incisions (PCRIs) reduce astigmatism, but toric IOLs do so to a greater extent as well as being more predictable, according to results of a recently published study.
Both toric IOLs and peripheral corneal relaxing incisions (PCRIs) reduce astigmatism, but toric IOLs do so to a greater extent as well as being more predictable, according to results of a study recently published in the Journal of Cataract & Refractive Surgery.
For this prospective masked bilateral randomized study, researchers from Moorfields Eye Hospital NHS Foundation Trust, London, enrolled 30 patients (60 eyes) with a preoperative corneal astigmatism of 1.0 to 2.5 D. All patients received a toric IOL in one eye and nontoric IOL plus PCRI in the other eye. Postoperative follow-up was done at 1 hour, 1 month and 6 months to measure uncorrected distance visual acuity, corrected distance visual acuity, autorefraction and subjective refraction. The IOL axis was assessed with retroillumination photos.
Researchers found a statistically significant difference in the mean astigmatism vector reduction in the toric IOL group compared with the PCRI group (1.74 D vs 1.27 D, respectively; P = 0.042). Mean absolute rotation of the toric IOL was 2.5 degrees (maximum 6.3 degrees) in the first 6 months postoperatively. Astigmatism increased in the PCRI group between the 1-month and the 6-month follow-up (mean: 0.38 D; maximum: 1.00 D; P
To view the abstract of this study, click here.
AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill
November 28th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.
AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials
November 24th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials